NCT06018415

Brief Summary

Investigators aim to compare the effects of early and late time-restricted feeding on overweight adults with metabolic syndrome

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
103

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 13, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

August 30, 2023

Completed
8 months until next milestone

Study Start

First participant enrolled

May 7, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 16, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 16, 2024

Completed
Last Updated

December 22, 2025

Status Verified

December 1, 2024

Enrollment Period

5 months

First QC Date

August 13, 2023

Last Update Submit

December 19, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Changes in body weight

    Body weight is assessed at the research center with the participants without shoes and in light clothing using a digital scale (OMRON MEDICAL Beijing Co., Ltd. HNH-318) to the nearest 0.1 kg.

    0-week; 6-week and 12-week

  • Changes in abdominal fat area

    Abdominal fat area is measured using bioelectrical impedance analysis (OMRON MEDICAL Beijing Co., Ltd. DUALSCAN, HDS-2000) to the nearest 1 cm2.

    0-week; 6-week and 12-week

Secondary Outcomes (7)

  • Changes in body composition ( body fat mass)

    0-week and 12-week

  • Changes in body composition (body muscle mass)

    0-week and 12-week

  • Changes in glycemic control

    0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c)

  • Changes in hemoglobin A1c (HbA1c)

    0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c)

  • Changes in total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)

    0-week; 6-week and 12-week

  • +2 more secondary outcomes

Study Arms (2)

Early time-restricted eating (eTRE)

EXPERIMENTAL

The eTRE group is instructed to consume all calories from 7 AM to 3 PM each day and fast from 3 PM to 7 AM

Behavioral: Early time-restricted eating (eTRE)

Late time-restricted eating (lTRE)

EXPERIMENTAL

The lTRE group is instructed toconsume all calories from 11 AM to 7 PM each day and fast from 7 PM to 11 PM

Behavioral: Late time-restricted eating (lTRE)

Interventions

The eTRE group is instructed to consume all calories in early 8h eating window,

Early time-restricted eating (eTRE)

The lTRE group is instructed to consume all calories in late 8h eating window.

Late time-restricted eating (lTRE)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age from 18 to 65 years
  • Body mass index (BMI): 24.0-40.0 kg/m2
  • Diagnosed with metabolic syndrome (i.e., more than 3 abnormal findings out of 5):
  • Waist circumference ≥ 90 cm (men) or ≥ 80 cm (women).
  • Elevated triglyceride (TG) (use of lipid-lowering medication is an alternate indicator) ≥ 150 mg/dL (1.7 mmol/L).
  • Reduced high-density lipoprotein cholesterol (HDL-c) (use of lipid-lowering medication is an alternate indicator) \< 40 mg/dL (1.0 mmol/L) in males \< 50 mg/dL (1.3 mmol/L) in females.
  • Elevated blood pressure (use of antihypertensive medication is an alternate indicator). Systolic blood pressure (SBP) ≥ 130 and/or diastolic blood pressure (DBP) ≥ 85 mmHg.
  • Elevated fasting blood glucose (FBG) (used of hypoglycemic medications is an alternate indicator) ≥ 100 mg/dL (5.6 mmol/L).

You may not qualify if:

  • Unstable weight (change \> 10% current body weight) for 3 months prior to the study
  • Pregnant or breast-feeding
  • Night shift workers
  • History of major diseases or related diseases, such as cancer, inflammatory disease, chronic obstructive pulmonary disease and major adverse cardiovascular event
  • Active viral hepatitis, acquired immune deficiency syndrome, syphilis and other sexually transmitted diseases, tuberculosis and other infectious diseases
  • Being treated with antibiotics or corticosteroids
  • Current participate in other weight-management program, current on a prescribed diet for special disease or current on any drugs that effect appetite
  • The researcher deemed it inappropriate to participate in the experimenter.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Affiliated Hospital of Xi 'an Jiaotong University

Xi'an, Shaanxi, 710061, China

Location

MeSH Terms

Conditions

Metabolic SyndromeOverweightObesityIntermittent Fasting

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsFastingFeeding BehaviorBehavior

Study Officials

  • Bingyin Shi

    First Affiliated Hospital Xi'an Jiaotong University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 13, 2023

First Posted

August 30, 2023

Study Start

May 7, 2024

Primary Completion

October 16, 2024

Study Completion

October 16, 2024

Last Updated

December 22, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

There is no plan to make individual participant data (IPD) available to other researchers.

Locations